PDMR/Director Shareholding, Issue of Equity & TVR

1 June 2026

Kromek Group plc 

("Kromek", the "Company" or the "Group") 

PDMR/Director Shareholding, Issue of Equity and Total Voting Rights

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that it has issued and allotted a total of 163,071 ordinary shares of 1p each in the Company ("Ordinary Shares") to satisfy the exercise of options by employees of the Company. This includes the exercise of 150,000 options by Berry Beumer, an Executive Director of the Company, on 28 May 2026. Following this exercise, Mr. Beumer has an interest in 230,000 Ordinary Shares, representing 0.03% of the Company's enlarged issued share capital.

Total voting rights

Application has been made to the London Stock Exchange for the 163,071 Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8 a.m. on or around 4 June 2026. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

Following Admission, the total number of Ordinary Shares in issue will be 655,299,911. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries 

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them